VRTX NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

Vertex Pharmaceuticals Inc · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 477.4 USD
-1.7% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is 3.9% above the Trend Line and sits at 67.1% of its 52-week range. The latest completed week returned -1.7%, after a -2.8% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is expensive relative to peers. Options positioning is bearish with 47/100 conviction, while the latest news-sentiment score is 56/100. Near-term considerations: volume confirmation is below normal; earnings are due in 2d.

Setup score 52 out of 100
Latest Close 477.4 USD 24 Jul 2026
1W Return -1.7% latest completed week
4W Return -2.8% short-term follow-through
12W Return 12.6% quarterly tape
Trend Breadth 30.8% 16 of 52 weeks active
Volume Ratio 0.8x vs 13-week average
What is working
  • The trend backdrop is active with a 2-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • Activity pressure is weak, so confirmation is not yet broad enough.
  • 3 reversal markers appear in the recent smart-money tape.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -1.7% Latest completed week; four-week move -2.8%. Indicator stack 24/89 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Positive 56.35% Historical one-week expectancy contributes to the evidence score when direction is confirmed. Options pressure Bearish 47/100 conviction; expected move 2.2%. News sentiment 56/100 62 relevant articles in the latest sentiment read. Event risk 2d Next report is scheduled for 03 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 3.9% above the Trend Line and sits at 67.1% of its 52-week range. The latest completed week returned -1.7%, after a -2.8% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.8x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.4412-week average 0.23

12-week confirmation

Trend active2/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure5/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership1/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.44Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers33 reversal markers

No recent accumulation markers. 3 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -2.8% over four weeks, 12.6% over 12 weeks, and 1.6% over one year. The current trend has remained active for 2 consecutive weeks.

Performance by holding period

1W-1.7%
4W-2.8%
12W12.6%
26W1.9%
52W1.6%
Active trend streak2 weeks
Active weeks in one year16
Trend breadth30.8%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.91Latest activity-pressure read.
Pressure change282.1%Four-week change in activity pressure.
Leadership-0.94Latest relative-leadership reading.
RS change64.7%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is expensive relative to peers.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 94% Model confidence 90%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength17/100Blend of value, momentum, and quality. Underlying universe rank 84; rank 1 is best.
Value8/100Relative valuation strength. Underlying universe rank 93; rank 1 is best.
Quality91/100Profitability and accounting quality. Underlying universe rank 10; rank 1 is best.
Momentum29/100Medium-term price momentum. Underlying universe rank 72; rank 1 is best.
Growth68/100Revenue and earnings growth. Underlying universe rank 33; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Value-quality framework52/100Value and quality alignment from the Sharemaestro SVQF framework.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
27.9x
Price divided by trailing earnings.
Price / sales
9.9x
Market value relative to trailing revenue.
EV / EBITDA
21.8x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
4.1%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
86.3%
Gross profit retained from each unit of revenue.
Operating margin
42.2%
Operating profit retained from revenue.
Free-cash-flow margin
38.9%
Free cash flow generated from revenue.
Return on invested capital
27.4%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
10.4%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
4/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
1.7%
Net share repurchases relative to market value.
Shareholder yield
1.7%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-0.7x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningBearish

VRTX shows bearish options pressure with a 47/100 conviction score, put-call volume ratio of 1.96, expected move of 2.2%, and Sharemaestro trend signal active.

Conviction47/100
Expected move2.2%
Put/call volume1.96
Pressure-35
Speculation41
Volatility46
Trend agreement72
Open options detail
Insider activity5 / 15

5 acquisitions and 15 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment56/100

Weighted news tone is neutral across 62 relevant articles.

22 positive · 38 neutral · 2 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings2dNext report is scheduled for 03 Aug 2026; event risk rises as the date approaches.
Options expected move2.2%Nearest-chain priced movement where available.
52-week drawdown-10.6%Distance below the 52-week high.
13-week volatility4.0%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher14 of 2612 weeks finished lower.
Best week+8.8%Week of 26 Jun.
Worst week-8.1%Week of 6 Mar.
Latest week-1.7%Week of 24 Jul.

Shape of recent returns

Strong gains3
Modest gains11
Flat weeks0
Modest losses9
Sharp losses3
Recent vol4.0%13-week weekly-return volatility.
Base vol4.5%52-week weekly-return volatility.
Up/down split30/22Count of positive and negative weeks in the 52-week window.
Average skew2.7% / -3.4%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape51/100

Trend, activity pressure, participation, and risk combine to a 51/100 tape read.

 Indicator analysis25/100

Latest 12-week confirmation: trend 2/12, activity pressure 5/12, relative leadership 1/12.

Activity pressure 0.44; 3 reversal markers Next-Week ExpectancyPositive 56.35%

Next-week expectancy is positive with a 56.35% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors36/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 25 SVQF52/100

Value and quality alignment from the Sharemaestro SVQF framework.

Composite rank 358.5 of 745 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options47/100

VRTX shows bearish options pressure with a 47/100 conviction score, put-call volume ratio of 1.96, expected move of 2.2%, and Sharemaestro trend signal active.

Bearish · Put-side pressure · Expected move 2.2% Sentiment56/100

Weighted news tone is neutral across 62 relevant articles.

Vertex Gears Up to Report Q2 Earnings: What Can Investors Expect? Insiders5 / 15

5 acquisitions and 15 disposals in the latest 180-day insider tape.

 Earnings2d

Next report is scheduled for 03 Aug 2026; event risk rises as the date approaches.

 Research flow1 items

1 recent research articles and 0 Market Watch posts are available.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 2026477.4 USD-1.7%459.4 USD437.1 USD0.91-0.946.1MOn
17 Jul 2026485.6 USD0.1%458.9 USD436.3 USD1.12-1.196.4MOn
10 Jul 2026485.4 USD-8.1%457.9 USD435.6 USD1.03-5.679.6MOff
3 Jul 2026528.0 USD7.5%456.8 USD434.7 USD0.703.977.1MOff
26 Jun 2026491.3 USD8.8%454.4 USD433.5 USD0.24-2.6515.0MOff
19 Jun 2026451.6 USD1.5%452.5 USD432.6 USD-0.26-14.807.5MOff
12 Jun 2026444.9 USD-0.4%451.7 USD431.9 USD-0.52-14.365.3MOff
5 Jun 2026446.8 USD-0.2%451.4 USD431.3 USD-0.69-12.596.7MOff
29 May 2026447.5 USD3.0%450.2 USD430.6 USD-0.81-16.885.3MOff
22 May 2026434.5 USD-0.6%449.4 USD429.8 USD-0.97-17.507.6MOff
15 May 2026436.9 USD1.7%449.0 USD429.2 USD-1.09-16.586.2MOff
8 May 2026429.8 USD1.4%448.3 USD428.6 USD-1.11-18.696.6MOff
1 May 2026423.9 USD-1.5%447.6 USD428.0 USD-1.16-15.994.8MOff
24 Apr 2026430.3 USD-2.5%446.9 USD427.6 USD-1.10-14.284.4MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.